PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.

$7.84
As of 10/15/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/21/2013
Outstanding shares:  15,604,605
Average volume:  59,793
Market cap:   $119,999,412
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    74275C205
ISIN:        US74275C2052
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   6.56
PS ratio:   0.00
Return on equity:   -61.77%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy